Praxis said Tuesday every patient in a study responded to its experimental epilepsy treatment. The biotech stock rocketed to a year high.
The post Praxis, A Top 1% Stock, Soars To Year-High After Epilepsy Treatment Scores Big appeared first on Investor’s Business Daily.